The filter features higher flux for biotherapeutics manufacturing
Chemical company Asahi Kasei Medical has recently launched the Planova FG1, a virus removal filter featuring higher flux for biotherapeutics manufacturing.
Planova FG1 will assist in the manufacture of biopharmaceuticals, plasma derivatives, biosafety testing services and biopharmaceutical CDMO operations. The aim is to improve productivity as the demand for monoclonal antibodies and other biopharmaceuticals grows by 5-10% per year.
“Asahi Kasei Medical is thrilled to launch the Planova FG1 next-generation virus removal filter,” said Asahi Kasei Medical president Ken Shinomiya. “We look forward to continuing to support biopharmaceutical manufacturers with our lineup of products that help them to safely and efficiently manufacture pharmaceuticals that patients can trust.”
Planova FG1 provides a high filtration speed and removal capacity. Its high flux enables virus filtration time to be shortened and better prevents virus breakthrough when the filtration process is suspended.
Even without a prefilter to remove aggregates, Planova FG1 allows for high protein filtration and virus removal performance. It is compatible with standard cleaning in place (CIP) and sterilisation in place (SIP) processes. This allows it to be compatible with a wide variety of existing biopharmaceutical manufacturing equipment.
The Planova product lineup has expanded heavily since its conception. The 2009 expansion offered the launch of Planova BioEX hydrophilic PVDF hollow-fibre membrane filters. The high flux of Planova FG1 is about seven times that of the Planova BioEX.
